Proteostasis nabs Belous from Galapagos for cystic fibrosis push

contract
Andrey Belous’ arrival coincides with the departure of Proteostasis Chief Medical Officer Po-Shun Lee. (Pixabay)

Proteostasis Therapeutics has named former Galapagos scientist Andrey Belous as its senior medical director. The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the chief medical officer position.

Belous spent a little more than a year at Galapagos, during which time he served as medical director for phase 3 development of autotaxin inhibitor GLPG1690 in idiopathic pulmonary fibrosis. Before joining Galapagos in 2018, Belous spent several years at The Medicines Company, where he played a role in projects including the clinical development of the anesthetic ABP-700.

Proteostasis’ new senior medical director arrives at the company during a low ebb in its tumultuous recent history. Having managed to generate some excitement about its cystic fibrosis pipeline in the past, Proteostasis was laid low in March by triplet data that underwhelmed analysts and investors.

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm ET | 11:00am PT

Join us Thursday, June 25th for a look at the current state of analytics in the life sciences industry. We will present the results from our industry survey with FiercePharma on how 100 of your peers are leveraging data analytics to respond to today’s challenges and generate timely, high value insights.

The data raised doubts about Proteostasis’ ability to compete with Vertex Pharmaceuticals, which is the current pacesetter in the race to develop more effective cystic fibrosis regimens. But with enough cash in the bank to see it through to 2021, Proteostasis is equipped to put its combinations through a phase 2 study and enter phase 3 by the middle of next year.

Proteostasis has put in place a new team to execute that clinical development plan. Belous’ arrival coincides with the departure of Po-Shun Lee, who served as CMO of Proteostasis over the past four years. Lee will continue to help Proteostasis as a consultant.

To replace Lee, Proteostasis has promoted its chief development officer. Gilmartin left AstraZeneca to take up the CDO position in 2016. Earlier in his career, Gilmartin was involved in the development of cystic fibrosis drugs including Kalydeco at Vertex, giving him experience Proteostasis thinks will help its prospects. 

“Geoff and Andrey bring deep experience in CF and lung fibrosis from their backgrounds at Vertex and Galapagos, respectively, and we look forward to their contributions in these roles,” Proteostasis CEO Meenu Chhabra said in a statement.

Suggested Articles

The minimally invasive device developer Lumendi reported that its system was used to perform its first fully incisionless appendectomy.

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.